Novel Drug Testing Technology Featured at AACC 2015
|
By LabMedica International staff writers Posted on 23 Aug 2015 |
|
The 2015 AACC Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA) featured new science and novel technology in all areas of clinical diagnostics. Market researcher Kalorama Information (New York City, NY, USA) attends the AACC meeting annually and notes developments for its reports on the in vitro diagnostic (IVD) market. Here, Kalorama notes the presentation of a unique approach to drugs-of-abuse testing via a new technology for urine-based drug testing.
“UR Code” by Marker Test Diagnostics, Inc. (Scottsdale AZ, USA) was designed to eliminate false-negative results that occur upon manipulation and observed-collection of samples, while providing an accurate and secure solution. It addresses sample integrity, one of the main issues in drug testing, as even under observation, sample adulteration or substitution is very common. UR Code is an orally taken marker that internally "bar-codes" a subject's urine. As observed-collections are invasive, inefficient, expensive, and require extensive organizational effort, UR Code aims to make sample substitution impossible while eliminating the need to supervise urine collection.
UR Code is a soft-gel capsule that provides a marker to code a person's urine. This code can only be detected through liquid chromatography-tandem mass spectrometry (LC-MS/MS). Neither the person providing the sample nor the soft-gel provider can predict which UR Code combination is given. The soft-gel capsule contains polyethylene glycol, a substance on the Food and Drug Administration's (FDA) list of inactive ingredients, cleared for humans and without side effects. Polyethylene glycols are not naturally found in urine and they have different molecular weights that enable the creation of 1,000 different marker types.
The test-subject takes the UR Code capsule under supervision. UR Code is absorbed, not metabolized, and quickly cleared through the kidneys. Thirty minutes later, urine can be collected without supervision. The laboratory then tests, using LC-MS/MS, whether the sample contains the correct code combination.
Kalorama’s latest comprehensive IVD market report—The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition—covers not only drugs-of-abuse testing and urinalysis but all major segments of clinical lab testing. The information presented in this report is derived on publicly available information sources. The analysis is based on the author's IVD industry knowledge combined with literature searches and interviews with industry professionals and experts. Hundreds of companies were tracked. This research is compiled along with the input of industry experts to produce an unparalleled vision of the IVD industry. The report includes market estimates and forecasts to 2018.
Related Links:
Kalorama Information
The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition
2015 AACC Annual Meeting & Clinical Lab Expo
.jpg)
“UR Code” by Marker Test Diagnostics, Inc. (Scottsdale AZ, USA) was designed to eliminate false-negative results that occur upon manipulation and observed-collection of samples, while providing an accurate and secure solution. It addresses sample integrity, one of the main issues in drug testing, as even under observation, sample adulteration or substitution is very common. UR Code is an orally taken marker that internally "bar-codes" a subject's urine. As observed-collections are invasive, inefficient, expensive, and require extensive organizational effort, UR Code aims to make sample substitution impossible while eliminating the need to supervise urine collection.
UR Code is a soft-gel capsule that provides a marker to code a person's urine. This code can only be detected through liquid chromatography-tandem mass spectrometry (LC-MS/MS). Neither the person providing the sample nor the soft-gel provider can predict which UR Code combination is given. The soft-gel capsule contains polyethylene glycol, a substance on the Food and Drug Administration's (FDA) list of inactive ingredients, cleared for humans and without side effects. Polyethylene glycols are not naturally found in urine and they have different molecular weights that enable the creation of 1,000 different marker types.
The test-subject takes the UR Code capsule under supervision. UR Code is absorbed, not metabolized, and quickly cleared through the kidneys. Thirty minutes later, urine can be collected without supervision. The laboratory then tests, using LC-MS/MS, whether the sample contains the correct code combination.
Kalorama’s latest comprehensive IVD market report—The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition—covers not only drugs-of-abuse testing and urinalysis but all major segments of clinical lab testing. The information presented in this report is derived on publicly available information sources. The analysis is based on the author's IVD industry knowledge combined with literature searches and interviews with industry professionals and experts. Hundreds of companies were tracked. This research is compiled along with the input of industry experts to produce an unparalleled vision of the IVD industry. The report includes market estimates and forecasts to 2018.
Related Links:
Kalorama Information
The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition
2015 AACC Annual Meeting & Clinical Lab Expo
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
Hepatitis B Test
OnSite HBsAg Rapid Test
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
- AACC: Better Quality and Patient-Friendliness Needed in Direct Testing
Channels
Clinical Chemistry
view channel
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read more
AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
Accurately monitoring drug levels in the blood is essential for effective treatment, particularly in the management of cardiovascular diseases. Traditional techniques for monitoring blood drug levels often... Read more
Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
Timely and accurate monitoring of renal function is essential for managing patients at risk of acute kidney injury (AKI), which affects about 12% of hospitalized patients and up to 57% of ICU patients.... Read more
Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
Nanopores are tiny openings that can detect individual molecules as they pass through, making them ideal for analyzing biomolecules like DNA and proteins. However, detecting proteins at extremely low ... Read moreMolecular Diagnostics
view channel
Portable Blood-Based Device Detects Colon Cancer
Colon cancer is the second leading cause of cancer-related deaths in the U.S., yet it is highly treatable when detected at an early stage. Traditional colonoscopy screenings, although effective, are unpleasant,... Read more
New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
Antimicrobial resistance has emerged as a significant global health threat, causing at least one million deaths annually since 1990. The Global Research on Antimicrobial Resistance (GRAM) Project warns... Read more
Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Cancer remains one of the leading causes of death globally, underscoring the critical need for more advanced, efficient, and early detection methods. Circulating tumor cells (CTCs) are cells that have... Read more
Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer
Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read moreHematology
view channel
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
WBC Count Could Predict Severity of COVID-19 Symptoms
The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. Cognitive impairment... Read more
New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
Accurate platelet count testing is a significant challenge for laboratories. Inaccurate results can lead to misdiagnosis, missed diagnoses, and delayed treatment for a variety of potentially fatal conditions,... Read more
Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
Heparin-induced thrombocytopenia (HIT), a serious side effect of the blood thinner heparin, is difficult to diagnose because thrombocytopenia, or low platelet count, can be caused by a variety of factors... Read moreImmunology
view channel
Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more
Microbiology
view channel
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Rapid PCR Testing in ICU Improves Antibiotic Stewardship
A collaborative study led by the University of Plymouth (Devon, UK) has shown that rapid polymerase chain reaction (PCR) testing in the intensive care unit (ICU) improved antibiotic stewardship compared... Read more
Pathology
view channel
New Test Diagnoses High-Risk Childhood Brain Tumors
Medulloblastoma, which originates in the cerebellum, the rear part of the brain, is the most prevalent malignant brain tumor in children and is notoriously difficult to diagnose. Currently, identifying... Read more
Informatics Solution Elevates Laboratory Efficiency and Patient Care
QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis
Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read moreIndustry
view channel
CACLP 2025 Unites Global Innovators in IVD Industry
CACLP (Shanghai, China) will be holding the 22nd China International In Vitro Diagnostic Expo, the largest and most influential gathering of the IVD industry in China, 22-24 March 2025 at the Hangzhou... Read more
Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). The acquisition remains subject to consultation with... Read more
